The entry data for the subjects in both parts of the study are shown in Tables 1 and 2. The mean age was 65 ± 6 years for the seven subjects in the pulsed nasal oxygen study. Their mean FVC was 1.4 ± 0.3 L and a mean FEW{ was 0.8 ±0.4 L. The mean age for the 17 subjects in the TTO study was 60.9 ±9.6 years. Their mean FVC was 2.6 ±2.3 L and mean FEWl was 1.2±0.6 L.

Pulsed Nasal Oxygen Study

The results of providing pulsed nasal oxygen with the various delay settings are shown in Figure 1. The mean room air Sa02 was 86.1 ± 3.0 percent. The mean Sa02 values at delay settings of 164, 100, 70, 25 and 1 ms were 91.1 ±2.4, 92.6±2.3, 93.6±1.9, 94.6±1.8 and 95.2 ±1.0 percent, respectively. The expiratory triggered pulse produced a mean Sa02 of 96.0 ± 1.0 percent. The Sa02 results in sequence were signifi­cantly different (p<0.01). The greatest difference was seen when comparisons were made between largest delay and the expiratory pulse (p<0.01).

FIGURE 1. The effect ofvarious

FIGURE 1. The effect of various delay settings of pulsed nasal oxygen on SaOs.

Pulsed and Continuous Transtracheal Oxygen Study

The results of providing continuous flow and pulsed TTO with the various delay settings are shown in Figure 2. The mean room air Sa02 was 86.0 ±2.6 percent. The mean continuous flow transtracheal Sa02 was 92.9 ±2.6 percent. There was no significant difference between Sa02 values from continuous flow and various pulse delays and the pre-inspiratory trig­gered pulse. However, the liter per minute flows of oxygen required to achieve an identical Sa02 for both continuous flow transtracheal and pulsed transtracheal delivery were 1.2 and 0.4 L/min, respectively (p<0.01). These data indicate that pulsed delivery of oxygen improved the efficiency of TTO administration by a factor of 3:1 over the short term of this study.
kamagra oral jelly 100mg

FIGURE 2. A comparison of continuous

FIGURE 2. A comparison of continuous flow and pulsed TTO with the various delay settings on Sa02.

Table 1—Entry Data for Nasal Oxygen Study

Patient

Age, yr

SaOa*

FVC

FEV,

1

67.00

84.00

1.40

0.48

2

72.00

84.00

1.20

0.50

3

57.00

84.00

1.40

0.41

4

75.00

91.20

1.00

0.50

5

59.00

86.00

1.30

0.86

6

64.00

83.30

2.00

1.60

7

62.00

90.00

1.60

1.20

Mean

65.14

86.07

1.41

0.79

SD

6.13

2.98

0.29

0.42

Table 2—Entry Data for Transtracheal Oxygen Study

Patient

Age, yr

FVC

FEV,

Po2*

Pco2

pH

1

66.00

3.60

1.46

48.00

39.00

7.44

2

52.00

2.15

1.37

49.00

41.00

7.52

3

46.00

1.18

0.41

48.00

46.00

7.44

4

80.00

4.94

2.16

44.00

34.00

7.48

5

60.00

1.50

0.65

47.00

39.00

7.41

6

60.00

1.82

0.71

38.90

41.00

7.46

7

65.00

1.61

0.56

36.00

57.00

7.42

8

65.00

2.75

1.44

52.00

36.00

7.44

9

69.00

2.26

1.21

49.00

30.00

7.42

10

60.00

5.91

2.38

47.00

38.00

7.54

11

69.00

2.51

1.37

40.00

48.00

7.45

12

37.00

2.01

0.67

59.00

29.00

7.47

13

62.00

2.28

1.03

41.00

45.00

7.44

14

53.00

0.93

0.75

54.00

52.00

7.45

15

60.00

3.01

1.25

45.00

46.00

7.42

16

62.00

1.54

0.49

49.00

45.00

7.47

17

70.00

3.46

2.13

39.00

35.00

7.42

Mean

60.94

2.56

1.18

46.23

41.24

7.45

SD

9.64

1.28

0.59

5.79

7.27

0.03

Category: Drugs / Tags: Pulsed Nasal, Transtracheal Oxygen Delivery

Leave a Reply

Your email address will not be published. Required fields are marked *

CAPTCHA image
*